SYNCOM/SE/2024-25 10th February, 2025

Online filing at: www.listing.bseindia.com and

https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai (M.H.) 400 001 BSE CODE:524470

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai- 400051 NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015 - Submission of Standalone & Consolidated Unaudited Financial Results along with Limited Review Report, for the quarter and Nine months ended on 31st December, 2024.

Dear Sir/Ma'am

This is in continuation of our letter no. SYNCOM/SE/2024-25 dated 3 rd February, 2025 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine months ended 31st December, 2024.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the following:

1. Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine months ended 31st December, 2024;
1. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter and Nine months ended 31st December, 2024;

which was considered and approved by the Board at their Meeting held on Monday, the 10th February, 2025 at 4:00 P.M. and Concluded at 4:30 P.M.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company.

The Financial Results will also be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

The Board Meeting commenced at 4:00 P.M. and Concluded at 4:30 P.M. You are requested to take on record the unaudited Financial Results along with Limited Review Report for your reference and record.

Thanking You, Yours Faithfully, For, SYNCOM FORMULATIONS (INDIA) LIMITED

CS VAISHALI AGRAWAL COMPANY SECRETARY & VAISHALI AGRAWAL Digitally signed by VAISHALI AGRAWAL Date: 2025.02.10 16:31:09 +05'30'

COMPLIANCE OFFICER Encl: a/a

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2024

							Rs. In Lacs except EPS
S.	Particulars	Quarter Ended			Nine months Ended		Year Ended
No.		$31 - 12 - 24$	$30 - 09 - 24$	$31 - 12 - 23$	$31 - 12 - 24$	$31 - 12 - 23$	$31 - 03 - 24$
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
$\mathbf{1}$	Revenue from Operations	12702.92	10149.25	6334.22	31438.60	18509.33	25835.96
$\overline{2}$	Other Income	382.49	418.35	434.89	1028.81	1022.98	1310.06
$\overline{3}$	Total Income $(1 + 2)$	13085.41	10567.60	6769.11	32467.41	19532.31	27146.02
$\overline{4}$	EXPENSES
	a) Cost of materials consumed	7626.18	6857.57	3774.65	19786.88	9365.04	13152.91 2620.83
	(b) Purchases of Stock-in-Trade	712.91	1260.24	398.25	2379.23	2132.22
	(c) Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	323.08	(1560.83)	(279.99)	(1501.04)	(198.06)	(218.10)
	(d) Employee benefits expense	1394.75	1240.39	973.63	3719.90	2636.54	3505.77
	(e) Finance costs	21.23	16.22	108.16	76.10	327.90	444.87
	(f) Depreciation and amortization expense	130.75	130.00	144.58	390.75	342.46	472.23
	(g) Other expenses	1186.03	1158.89	787.71	3450.30	2668.67	3989.12
	Total expenses (4)	11394.93	9102.48	5906.99	28302.12	17274.77	23967.63
5	Profit/(loss) before exceptional items and tax (3-4)	1690.48	1465.12	862.12	4165.29	2257.54	3178.39
6	Exceptional Items	0.00	(0.24)	(2.39)	(0.24)	(2.39)	(2.39)
$\overline{7}$	Profit/(loss) before tax (5 - 6)	1690.48	1464.88	859.73	4165.05	2255.15	3176.00
8	Tax expense:
	(1) Current tax	402.82	348.55	207.81	995.14	516.52	758.25 55.43
	(2) Deferred tax	8.54	21.33	9.85	32.93	51.16
9	Profit (Loss) for the period from continuing operations (7-8)	1279.12	1095.00	642.07	3136.98	1687.47	2362.32
	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
10 11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)		0.00	0.00	0.00	0.00	0.00
		0.00 1279.12	1095.00	642.07	3136.98	1687.47	2362.32
13	Profit/(loss) for the period (9+12)
14	Other Comprehensive Income A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to
	profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	18.40	391.88	185.71	686.21	516.82	681.39
	(ii) Income tax relating to items that will be reclassified to profit					0.00	0.00
	or loss	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive
	Income for the period)	1297.52	1486.88	827.78	3823.19	2204.29	3043.71
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	0.00		0.00		0.00	19245.18
18	Earnings per equity share (for continuing operation):
	$(1)$ Basic	0.14	0.16	0.09	0.41	0.23	0.32
	(2) Diluted	0.14	0.16	0.09	0.41	0.23	0.32
19	Earnings per equity share (for discontinued operation):						0.00
	$(1)$ Basic	0.00	0.00	0.00	0.00 0.00	0.00 0.00	0.00
	(2) Diluted	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)
	(1) Basic	0.14	0.16	0.09	0.41	0.23	0.32
	(2) Diluted	0.14	0.16	0.09	0.41	0.23	0.32

Place: Indore

Date: 10-02-2025

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda Chairman & Wholetime Director DIN: 00023050

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

SYNCOM Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775 E Mail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759 STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY UNAUDITED RESULTS Quarter Ended Nine months Ended Previous Year S. No Particulars $31 - 12 - 24$ $30 - 09 - 24$ $31 - 12 - 23$ $31 - 12 - 24$ $31 - 12 - 23$ $31 - 03 - 24$ Unaudited Unaudited Unaudited Unaudited Unaudited Audited Segment Revenue a) Pharmaceuticals Drugs & Formulations 12766.27 10218.43 6554.80 31570.03 18370.09 b) Trading of Commodities 228.88 $251.10$ 114.39 612.39 857.41 c) Renting of Property $90.26$ 98.07 99.92 284.99 304 81 Total Segment Revenue 13085.4 10567.60 6769.1 $32467.4$ 19532.31 Less: Inter Segment Revenue $0.00$ $0.00$ $0.0$ $0.00$ $0.00$ Revenue from Operations 13085.41 10567.60 6769.1 $32467.4$ 1953231 $\overline{2}$ Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations 1626 16 1382.69 873.62 3964.21 2293.30 b) Trading of Commodities $3.37$ 8.40 $-1.11$ 16.16 $-1.43$ c) Renting of Property 82.18 $90.0^{\circ}$ 95.38 260.78 291.18 Total Profit before tax $1711.7$ 1481.10 967.89 4241.15 2583.05 Less: i) Interest $\frac{21.25}{21.25}$ $16.22$ $108.16$ $76.10$ 327.9 ii) Other Un-allocable Expenditure $0₀$ $0₀$ $0.00$ $0.00$ $0.00$ Profit before tax 1690.48 1464.88 859.73 4165.05 2255.15 $\overline{\mathbf{3}}$ (Segment Asset-Segment Liabilities) Segment Asset a) Pharmaceuticals Drugs & Formulations 32536.81 31234.08 36167.12 3253681 3616712 b) Trading of Commodities 890.60 971.86 $41.27$ 890.60 $41.2$ c) Renting of Property 4733.45 4733.45 4733.45 4740.64 4740.64 Total Segment Asset 38160.86 36939.39 40949.03 38160.86 40949.03 Un-allocable Assets $0.00$ $0.00$ $0.00$ $0.0($ $0.00$ Net Segment Asset 38160.86 36939.39 40949.03 38160.86 40949.03

Notes:-

Segment Liabilities

c) Renting of Property

b) Trading of Commodities

Total Segment Liabilities

Un-allocable Liabilities

Net Segment Liabilities

a) Pharmaceuticals Drugs & Formulations

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 10/02/2025.

These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 2 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

5460.01

155.00

77.48

$0.0$

569249

5692.49

5432.16

243.87

92.52

$0⁰$

5768 55

5768.55

12936.79

52.11

$163.9$

$0₀$

1315281

13152.81

5460.01

155.00

$77.48$

$0⁰$

5692 49

5692.49

The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as 3 required

As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/nine months ended on 31st December, 4 2024. The report does not have any impact on the above results and notes which needs explanation.

5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

Place: Indore Date: 10/02/2025

FOM Fo MOW

For, Syncom Formulations (India) Limited

12936.79

52.11

163.9

$0₀$

13152.81

Kedarmal Shankarlal Bankda Chairman & Wholetime Director DIN: 00023050

Ended

25.672.79

1.071.34

27146.02

3,232.76

18.49

369.62

3620.87

444.87

3176.00

33.390.18

1.026.45

4,733.45

39150.08

10,181.37

151.93

171.60

$000$

10504.90

$0.00$

401.89

$0.00$

SANJAY MEHTA & ASSOGIATES

Ch artered Accountants

338, Saket Nagar, lndore - 452 018 (M.P.) Phone : 0731-2563625, 427 4391, ⁹⁴²⁵⁰6& E-mail : ofEce@srnaonline-in

Limited Review Report on Un-audited Standalone Financial Results for the euarter & Nine Months ended 3l'r December,,2024 pursuant to Regulation 33 of the SEBI (LODRiRegulations,20l5

To,

The Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED lndore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of SyNCOM FORMULATIONS (INDIA) LIMITED ("the Company"), for the period ended December, 31,2024 (,,the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations,2ol5, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and -"u.r..."rt principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting; ("fND AS 34',), prescriLed under Section 133 of the Cornpanies Act, 2013, and other Accounting principles generally accepted- in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations,ZOIS, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements hased on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 241C, "Review oflnterim Financial Infonnation performed by the Indepenrlent Audiror o7 thiditiry", iisued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain rnoderate assurance as to whether the financial statementr u.i f.e" of rnateiial misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to filancial data and thus provide less assttrance than an audit. We have not performed an audiiand accordingly, *. do not express an audit opitrion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance wiih applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in tenns of Regrilation ³³of the SEBI (Listing Obligations and Disclosures Requirements) Regulations,20l5,including the minner in which it is to be disclosed, or that it contains any material misstatemcnt.

Place: Indore Date: 10tr' February, ²⁰²⁵ CA Manish Mittal

Foro Sanjay Mehta &Associates Chartered Accoufffoits FRN:011524C

(Partner) M. No. 079452 ffimw7 UDIN : 2507 9 452BMIGQK2 053

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- [email protected], Website:- www.sfil.in, CIN:- L24239MH1988PLC047759

INAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTH ENDED 31ST DECEMBER, 2024

						Rs. In Lacs except EPS
S.	Particulars	Quarter Ended			Nine months Ended		Year Ended
No.		$31 - 12 - 24$	30-09-24	$31 - 12 - 23$	$31 - 12 - 24$	$31 - 12 - 23$	$31 - 03 - 24$
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
$\mathbf{1}$	Revenue from Operations	12753.32	10231.42	6513.95	31613.62	18881.42	26338.71
$\overline{2}$	Other Income	403.70	414.92	455.54	1049.12	1042.75	1352.59
$\overline{3}$	Total Income $(1 + 2)$	13157.02	10646.34	6969.49	32662.74	19924.17	27691.30
4	EXPENSES					9365.04	13152.91
	(a) Cost of materials consumed	7626.18 722.62	6857.57 1266.24	3774.65 450.11	19786.88 2417.47	2208.64	2710.59
	(b) Purchases of Stock-in-Trade (c) Changes in inventories of finished goods, Stock-in- Trade and						(175.46)
	work-in-progress	316.76	(1543.72)	(271.89)	(1507.36)	(155.42)
	(d) Employee benefits expense	1394.75	1240.39	973.63	3719.90	2636.54	3505.77
	(e) Finance costs	19.82	15.96	108.16	74.81	327.90	447.41
	(f) Depreciation and amortization expense	130.75	130.00	144.58	390.75	342.46	472.23
	(g) Other expenses	1219.92	1194.83	851.74	3558.79	2804.32	4180.16
	Total expenses (4)	11430.80	9161.27	6030.98	28441.24	17529.48	24293.61
5	Profit/(loss) before exceptional items and tax (3-4)	1726.22	1485.07	938.51	4221.50	2394.69	3397.69
$6\phantom{1}$	Exceptional Items	0.00	(0.24)	(2.39)	(0.24)	(2.39)	(2.39)
$\overline{7}$	Profit/(loss) before tax (5 - 6)	1726.22	1484.83	936.12	4221.26	2392.30	3395.30
8	Tax expense:		352.92	226.10	1014.43	550.17	808.45
	(1) Current tax	417.61 8.41	21.33	9.85	32.80	51.16	55.43
9	(2) Deferred tax Profit (Loss) for the period from continuing operations (7-8)
		1300.20	1110.58	700.17	3174.03 0.00	1790.97 0.00	2531.42 0.00
10	Profit/(loss) from discontinued operations	0.00	0.00 0.00	0.00 0.00	0.00	0:00	0.00
11	Tax expense of discontinued operations Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00
12		0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9+12)	1300.20	1110.58	700.17	3174.03	1790.97	2531.42
14	Other Comprehensive Income			0.00	0.00	0.00	0.00
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	18.40	391.88	185.71	686.21	516.82	681.39
	(ii) Income tax relating to items that will be reclassified to profit or loss			0.00	0.00	0.00	0.00
		0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for
	the period)	1318.60	1502.46	885.88	3860.24	2307.79	3212.81
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	0.00	0.00	0.00	0.00	0.00	19414.28
18	Earnings per equity share (for continuing operation):
	$(1)$ Basic	0.14	0.16	0.09 0.09	0.41 0.41	0.25 0.25	0.34 0.34
	(2) Diluted	0.14	0.16
19	Earnings per equity share (for discontinued operation):	0.00	0.00	0.00	0.00	0.00	0.00
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
20	(2) Diluted Earnings per equity share (for discontinued & continuing operations)
					0.41	0.25	0.34
	$(1)$ Basic	0.14 0.14	0.16 0.16	0.09 0.09	0.41	0.25	0.34
	(2) Diluted

$\overline{\phantom{a}}$

Place: Indore

Date: 10/02/2025

Kedarmal Shankarlal Bankda

Chairman & Wholetime Director DIN: 00023050 $\mathbb{Z}$

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- [email protected], Website:- www.sfil.in, CIN:-124239MH1988PLC047759

VENUE, RESULTS ALONG WITH QUARTERLY/NINE MONTHS ENDED 31/12/2024 UNAUDITED RESULTS

			Quarter Ended			Nine months Ended	Previous Year Ended
			$30 - 09 - 24$	$31 - 12 - 23$	$30 - 12 - 24$	$31 - 12 - 23$	$31 - 03 - 24$
S. No.	Particulars	$31 - 12 - 24$ Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
							26,218.06
$\mathbf{1}$	Segment Revenue	12839.41	10298.07	6755.87	31767.79	18763.54	1.071.34
	a) Pharmaceuticals Drugs & Formulations	228.88	251.10	114.39	612.39	857.41 303.22	401.89
	b) Trading of Commodities	88.73	97.17	99.23	282.56	19924.17	27691.30
	c) Renting of Property	13157.02	10646.34	6969.49	32662.74		0.00
	Total Segment Revenue	0.00	0.00	0.00	0.00	0.00	27691.30
	Less: Inter Segment Revenue	13157.02	10646.34	6969.49	32662.74	19924.17
	Revenue from Operations
$\overline{2}$	Segment Results Profit(+)/Loss(-) before tax						3.454.60
	and interest from each segment	1662.02	1403.28	950.71	4021.56	2432.05	18.49
	a) Pharmaceuticals Drugs & Formulations	3.37	8.40	$-1.11$	16.16	$-1.43$	369.62
	b) Trading of Commodities	80.65	89.11	94.69	258.35	289.59	3,842.71
	c) Renting of Property	1746.04	1500.79	1044.29	4296.07	2720.21	447.41
	Total Profit before tax	19.82	15.96	108.16	74.81	327.90
	Less: i) Interest	0.00	0.00	0.00	0.00	0.00	0.00 3395.30
	ii) Other Un-allocable Expenditure	1726.22	1484.83	936.13	4221.26	2392.31
	Profit before tax
$\mathbf{3}$	(Segment Asset-Segment Liabilities)
	Segment Asset	32946.55	31539.20	35680.64	32946.55	35680.64	34,706.49
	a) Pharmaceuticals Drugs & Formulations	890.60	971.86	41.27	890.60	41.27	1,026.45
	b) Trading of Commodities	4733.45	4733.45	4740.64	4733.45	4740.64	4,733.45
	c) Renting of Property	38570.60	37244.51	40462.55	38570.60	40462.55	40466.39 0.00
	Total Segment Asset	0.00	0.00	0.00	0.00	0.00
	Un-allocable Assets	38570.60	37244.51	40462.55	38570.60	40,462.55	40,466.3
	Net Segment Asset
	Segment Liabilities	5663.64	5552.20	12346.75	5663.64	12346.75	11,328.5
	a) Pharmaceuticals Drugs & Formulations -	155.00	243.87	52.11	155.00	52.11	151.9 171.6
	b) Trading of Commodities	77.43	92.52	163.91	77.43	163.91
	c) Renting of Property	5896.07	5888.59	12562.77	5896.07	12562.77	11652.1
	Total Segment Liabilities	0.00	0.00	0.00	0.00	0.00	0.0
	Un-allocable Liabilities	5896.07	5888.59	12562.77	5896.07	12562.77	11652.1
	Net Seament Liabilities

Notes:-

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 10/02/2025. 2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, ר בווססט מטעצפ וסטווס ומצע טפטון מוסף מודע שוויט ווי לשוויט אווי הוא מודע האיט אוויסט של האוויסט ווי הוא הייסט
2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given

4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/nine months ended on 31st December, 2024. The report does not have any impact on the above results and notes which needs explanation.

5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 6 The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd. Sante Biotech Pvt Ltd. and Vincit Biotech International Pvt. Ltd.

Place: Indore

Date: 10/02/2025

OM FO

Kedarmal Shankarlal Bankda Chairman & Wholetime Director

DIN: 00023050

SANJAY MEHTA & ASSOCIATES

Chartered Accountants

$\pi$ d

338, Saket Nagar, Indore - 452 018 (M.P.) Phone: 0731-2563625, 4274391, 94250 62964 E-mail: [email protected]

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Nine Months ended 31st December, 2024 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To. The Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended December 31, 2024 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
1. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

S. No.	Name of the Company	Relationship with the Holding Company
	1. Sante Biotech Pvt. Ltd.
	2. Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
	3. Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary Wholly Owned Subsidiary

The Statement includes the results of the following entity:

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 20l5,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates Chartered Accof,ftants FRN:011521C

(Partner)

,frmz.\ ,/:- s>z/

Place: Indore I)ate: 10th February,2025 CA Manish Mittal

M. No. 079452 UDIN: 2507 9 452BMIGQL93 I 7

AI assistant

Syncom Formulations (India) Ltd. Interim / Quarterly Report 2025

60987_rns_2025-02-10_5f999fcd-e6a8-4bd1-aac4-9bfbb7aac1d5.pdf

SYNCOM FORMULATIONS (INDIA) LIMITED